Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915129 · ClinicalTrials.gov registry record · NA
The Effect of Galactooligosaccharides (GOS) on the Gut Microbiota of Lactose Intolerance Individuals
A NA study, sponsored by Oregon State University.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT06915129: Completed NA study, sponsored by Oregon State University.
NCT06915129 is a NA study that has completed, run by Oregon State University. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06915129, a NA study, has completed, sponsored by Oregon State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study was to identify specific microbes that change with supplementation with galactooligosaccharides-prebiotics that are associated with alleviation of lactose intolerance symptoms in lactose-intolerant human subjects.
Primary Outcome
DNA was extracted from 200 mg of fecal samples Hilden, Germany). The concentration of extracted DNA was measured by Fluorometer, followed by a library construction targeting the V4 region of the 16S rRNA gene for microbiome sequencing. Microbiome compositional analysis and statistical analysis was performed to identify shifts in specific microbes over time with prebiotic GOS supplementation.
Interventions
- DIETARY_SUPPLEMENT Prebiotic galactooligosaccharides (GOS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-10-25 |
| Est. Completion | 2021-12-06 |
| Phase | NA |
What the finished NCT06915129 record still lists
NCT06915129 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Prebiotic galactooligosaccharides (GOS) is the first listed.
NCT06915129 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06915129 about?
NCT06915129 is a clinical study titled "The Effect of Galactooligosaccharides (GOS) on the Gut Microbiota of Lactose Intolerance Individuals". The purpose of this study was to identify specific microbes that change with supplementation with galactooligosaccharides-prebiotics that are associated with alleviation of lactose intolerance symptoms in lactose-intolerant human subjects.
What is the current status of trial NCT06915129?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2021-10-25. Estimated completion is 2021-12-06.
What interventions are being tested in trial NCT06915129?
The interventions under investigation include: Prebiotic galactooligosaccharides (GOS) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06915129?
This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06915129's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI